- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- October 2024
- 183 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- August 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- May 2024
- 136 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- August 2022
- 118 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- February 2024
- 94 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- June 2023
- 132 Pages
Global
From €903EUR$950USD£759GBP
- Report
- January 2023
- 359 Pages
Global
From €3394EUR$3,570USD£2,851GBP
The Opioid Induced Constipation Drugs market is a subset of the Gastrointestinal Drugs market. It is composed of drugs used to treat constipation caused by opioid use. These drugs are typically used to reduce the severity of constipation and improve the quality of life for those taking opioids. Commonly used drugs in this market include methylnaltrexone, naloxegol, and lubiprostone. These drugs work by blocking opioid receptors in the gastrointestinal tract, thus reducing the constipation-causing effects of opioids.
The Opioid Induced Constipation Drugs market is a growing market, as opioid use continues to rise. This market is expected to continue to grow as more people are prescribed opioids for pain management.
Some companies in the Opioid Induced Constipation Drugs market include Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., and Salix Pharmaceuticals, Ltd. Show Less Read more
